Pyxis Oncology, Inc. (PYXS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	11.0M	13.9M	16.1M	—	—
Cost of Revenue	27.0K	2.4M	475.0K	—	—
Gross Profit	11.0M	11.5M	15.7M	—	—
Operating Expenses
R&D Expense	75.2M	73.7M	58.7M	49.6M	86.1M
SG&A Expense	24.5M	22.2M	25.4M	32.6M	37.4M
General & Admin Expense	25.2M	22.2M	25.4M	32.6M	37.4M
Selling & Marketing Expense	(684.0K)	—	—	—	—
Other Expenses	3.4M	—	21.0M	—	—
Total Operating Expenses	103.1M	95.9M	105.1M	82.2M	123.5M
Cost and Expenses	103.1M	98.3M	105.6M	82.2M	123.5M
Operating Income (EBIT)	(92.1M)	(84.4M)	(89.5M)	(82.2M)	(123.5M)
Non-Operating
Interest Income	1.8M	3.6M	7.0M	6.6M	2.8M
Interest Expense	—	—	—	—	—
Net Interest Income	1.8M	3.6M	7.0M	6.6M	2.8M
Other Non-Op Income/Expense	4.5M	6.2M	10.0M	8.4M	2.8M
Non-Operating Income (excl Interest)	(4.5M)	(6.2M)	(21.0M)	(8.4M)	(2.8M)
EBT (Pre-Tax Income)	(87.6M)	(78.2M)	(79.5M)	(73.8M)	(120.7M)
Income Tax Expense	1.1M	1.4M	(2.2M)	—	—
Bottom Line
Net Income	(88.7M)	(79.6M)	(77.3M)	(73.8M)	(120.7M)
Earnings from Cont. Ops	(88.7M)	(79.6M)	(77.3M)	(73.8M)	(120.7M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(88.7M)	(79.6M)	(77.3M)	(73.8M)	(120.7M)
Per Share
Basic EPS	($1.41)	($1.28)	($1.32)	($1.85)	($3.57)
Diluted EPS	($1.41)	($1.28)	($1.32)	($1.85)	($3.57)
Revenue Per Share	$0.17	$0.22	$0.28	$0.00	$0.00
Shares
Basic Shares Outstanding	64.0M	62.1M	58.4M	39.9M	33.0M
Diluted Shares Outstanding	64.0M	62.1M	58.4M	39.9M	33.0M
Profitability Metrics
EBITDA	(83.4M)	(73.7M)	(65.5M)	(71.9M)	(120.0M)
D&A	4.2M	4.5M	3.0M	1.9M	709.0K
EBIT	(87.6M)	(78.2M)	(68.5M)	(73.8M)	(120.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026